Shattuck Labs Announces Participation in Upcoming Piper Sandler Virtual Novel Targets in Immunology Symposium

Core Insights - Shattuck Labs, Inc. is participating in the Piper Sandler Virtual Novel Targets in Immunology Symposium on February 12-13, 2026, where company management will engage in a fireside chat [1][2] Company Overview - Shattuck Labs, Inc. is a clinical-stage biotechnology company focused on developing novel therapeutics for inflammatory and immune-mediated diseases, with a lead program centered on SL-325, a potential first-in-class antibody targeting the DR3/TL1A pathway [4] - The company has expertise in protein engineering and aims to provide innovative treatments for conditions such as inflammatory bowel disease (IBD) [4] Product Development - SL-325 is a Death Receptor 3 (DR3) blocking antibody designed for complete and durable blockade of the DR3/TL1A pathway, showing high affinity binding and superior activity compared to TL1A antibodies in preclinical studies [3] - SL-325 is currently undergoing evaluation in a Phase 1 clinical trial and has demonstrated a favorable safety profile in non-human primates [3]